RegisterLogin

BRD5529

CAT: 0804-HY-115497-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-115497-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
BRD5529 is an effective dose-dependent CARD9-TRIM62 protein–protein interaction (PPI) inhibitor with an IC50 value of 8.6 μM. BRD5529 has potency and complete inhibition of CARD9 ubiquitinylation in vitro, also has favorable solubility. BRD5529 can be used for the research of inflammatory bowel disease (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC) [1][2].
CAS Number
[1358488-78-4]
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
E1/E2/E3 Enzyme
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/brd5529.html
Purity
98.94
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(C1=CC(NC(C2=CC=C(C)C=C2)=O)=CN=C1N3CCC(N4CCCCC4)(C(N)=O)CC3)O
Molecular Formula
C25H31N5O4
Molecular Weight
465.54
Precautions
H315, H319, H335
References & Citations
[1]Leshchiner ES, et al. Small-molecule inhibitors directly target CARD9 and mimic its protective variant in inflammatorybowel disease. Proc Natl Acad Sci U S A. 2017 Oct 24;114 (43) :11392-11397.|[2]Theodore J Kottom, et al. Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9. Drugs R D. 2022 Jun;22 (2) :165-173.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-123815-01BRD5459
HY-136251-01BRD0539
HY-15647-01BRD9539
HY-19694-01BRD7552
HY-116736BRD7539

Alternative Products

CatalogName
M11471-01BRD5529

Popular Products